China Tuberculosis Policy at Crucial Crossroads: Comparing the Practice of Different Hospital and Tuberculosis Control Collaboration Models Using Survey Data

Xiaolin Wei1, Guanyang Zou2, John Walley3, Jia Yin1, Knut Lonnroth4, Mukund Uplekar4, Weibing Wang5, Qiang Sun6*

1 School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China, 2 China HSD Program, Nuffield Centre for International Health and Development, University of Leeds, Leeds, United Kingdom, 3 Nuffield Centre for International Health and Development, University of Leeds, Leeds, United Kingdom, 4 Global TB Programme, the World Health Organization, Geneva, Switzerland, 5 School of Public Health, Fudan University, Shanghai, China, 6 Center for Health Management and Policy, Shandong University, Jinan, China

Abstract

Background: Currently three hospital and tuberculosis (TB) collaboration models exist in China: the dispensary model where TB has to be diagnosed and treated in TB dispensaries, the specialist model where TB specialist hospital also treat TB patients, and the integrated model where TB diagnosis and treatment is integrated into a general hospital. The study compared effects of the three models through exploring patient experience in TB diagnosis and treatment.

Methods: We selected two sites in each model of TB service in four provinces of China. In each site, 50 patients were selected from TB patient registries for a structured questionnaire survey, with a total of 293 patients recruited. All participants were newly registered uncomplicated TB cases without any major complications or resistance to first-line anti-TB drugs, and having successfully completed treatment. Diagnostic and treatment procedures were reviewed from medical charts of the surveyed patients to compare with national guidelines.

Results: Specialist sites had the highest patient expenditure, hospitalization rates and mostly used second-line anti-TB drugs, while the integrated model reported the opposite. The median health expenditure was USD 1,499 for the specialist sites and USD 306 for the integrated sites, with 83% and 15% patients respectively having unnecessary hospitalization. 74% of the specialist sites and 19% of the integrated sites used second-line anti-TB drugs. Mixed results were identified in the two dispensary sites. One site had median health expenditure of USD 138 with 12% of patients hospitalized, while the other had USD 912 and 65% respectively.

Conclusion: The study observed prohibitive financial expenditure and a high level of deviation from national guidelines in all sites, which may be related to the profit-seeking behavior of public hospitals. The study supports the integrated model as the better policy option for future TB health reform in China.

Citation: Wei X, Zou G, Walley J, Yin J, Lonnroth K, et al. (2014) China Tuberculosis Policy at Crucial Crossroads: Comparing the Practice of Different Hospital and Tuberculosis Control Collaboration Models Using Survey Data. PLoS ONE 9(3): e90596. doi:10.1371/journal.pone.0090596

Introduction

Tuberculosis is a global threat to public health, with around 12 million cases and 1 million deaths in 2011 [1]. In all countries, the national TB programs play the leading role in implementing the World Health Organization (WHO) program. It is vital to include other health providers such as hospitals and private doctors in the treatment programme and ensure they follow the international standards of TB care [2]. Hospitals are usually the major providers of healthcare but they are often outside of the national TB programs. Hospitals may treat TB patients in a way different from the national TB guidelines. Substandard TB treatment, long delays and higher defaults had been reported in patients treated in big hospitals in Asian and African countries [3–5]. In China, public hospitals are the dominant health providers, and have decisive impacts on the TB program in terms of the key WHO TB control targets such as case detection and treatment success [6]. However, little is known in China regarding how hospitals collaborate with the TB control program.

China has the second highest TB burden in the world with 1.4 million patients [1]. The WHO Stop TB program (commonly called “DOTS”) was adopted in China since the early 90s. In
The integrated model
The specialist model
The dispensary model

The integrated model
This is a new development. A clinic provides TB care, under the free treatment policy, in a general hospital. The hospital is often the most popular local general hospital in the district, and is called as the TB ‘designated’ hospital. Patients in this model are diagnosed and treated under the TB program in the designated hospital. Other health providers including general hospitals should refer suspects and patients to the designated hospital. Under this model, the TB dispensary continues to provide the public health service aspects of TB control; such as training, mass education, case supervision, reporting and ensuring referred TB suspects arrived in the designated hospital. The model initiated in eastern China, and is practiced in Shanghai, Zhejiang, Jiangsu in 2002, and has expanded to a few sites in western provinces such as Guangxi.

China’s case detection rates was low in early 2000s, mainly due to the weak linkage between public hospitals and TB dispensaries [9]. China’s public hospitals were paid on fee-for-service basis, and relied heavily on user fees and drug margins for revenue [10]. A national TB survey in 2000 showed that 91% of TB patients visited hospitals first, while only 25% of TB suspects in hospitals were referred to TB dispensaries [11]. Patients treated in public hospitals were financially depleted and always severely delayed their diagnosis for TB [12–14].

The hospital TB collaboration has improved since 2005 thanks to the Internet based communicable disease reporting system developed after the Severe Acute Respiratory Syndrome (SARS) outbreak. All public hospitals are required to report TB suspects and cases online within 24 hours on the reporting system [15]. In addition, the Ministry of Health published guidelines to improve the collaboration between general hospitals and TB dispensaries [16]. All the above efforts substantially improved China’s case detection since 2005 [17]. However, profit-seeking behaviour in China’s public hospitals remains, which continued to cause high costs for TB patients [18,19].

The current policy debates on the future of China’s TB control system. Rising of multi-drug resistance (MDR) TB and other complex TB cases pose a great clinical challenge to TB dispensaries [20]. An argument posited that the specialist TB hospital has good clinical capacity, so it should treat all TB cases including drug sensitive patients. Another argument favoured the integrated model because people normally visit a general hospital for initial treatment. However, no supporting evidence is available for either argument. In response, this study aims to compare patient care experience within the different TB control models.

We choose specifically drug sensitive patients because they account for the majority of TB patients. The study objective is to identify which model provides the best care for drug sensitive patients and with the least patient out-of-pocket expenditure.

Methods
Design of the study and settings
A facility level analysis was employed. Because the number of facilities for each model was not known, two sites of each model were purposively selected, with one urban and relatively rich site with gross domestic product (GDP) per capita over RMB20,000/USD2941, and another rural and relatively poor site with GDP per capita below RMB20,000. Due to the limited choices of sites with the integrated model, we selected one in Shanghai (east) and another in Guangxi (southwest). Both sites have started the integrated model for three years. The sites with specialist model were selected in Shandong province where the specialist model is more prevalent. The dispensary sites are widely available in China. We selected one in Zhejiang of eastern China and the other in Guangxi of western China. Each site consisted of a county/district where the basic TB management unit was located. ZD, SL and SC were relatively rich sites, while GP, SDC and GN were relatively poor sites. Full site names were blinded for confidentiality reasons. In the selected sites, general hospitals received less than 10% of their revenue from the government, while specialist hospitals received 20–30% from government.

Public health agencies, TB dispensaries received around 85% of their revenues from the government.

Patient recruitment
Only uncomplicated TB cases were recruited for comparison reasons because this group of patients accounts for the majority of total TB patients in China. Each site had around 100 uncomplicated TB cases registered in a year. We randomly selected 50 cases from its TB registry according to the inclusion criteria: 1) being new sputum smear positive or negative pulmonary TB patients, 2)
been registered in 2007 and successfully completed treatment by August 2008, and 3) having no record of any serious co-morbidities such as diabetes, cardiovascular disease, hepatic disease or severe respiratory symptoms. All selected patients treated in the specialist hospitals were sensitive to first-line anti-TB drugs. Drug sensitivity tests were not available in other models. But all cases were unlikely to be drug resistant as they were recorded as ‘treatment successfully completed’. Participants were surveyed using a structured questionnaire adapted from the National TB Survey [11] which had been used in other similar settings [21,22]. Questions covered patient social-economic status, care pathways, patient expenditure on TB care, and delays. Costs covered by health insurance schemes and the free treatment policy were often deducted automatically at the point of payment, so patients were not aware of the exact amount of costs covered by health insurance or the free treatment policy. Thus, we only collected patient out-of-pocket health expenditure. Patient charts provided information on medical examinations and drugs prescription.

Ethics statement
All data were collected by a team of experienced researchers in 2008. Ethical approval was granted by the Ethical Committee for Health Policy Studies in Shandong University, China. All the subjects provided written informed consents. The dataset would be made available to researchers who formally apply through the corresponding author and comply with requirements of the Ethical Committee.

Analysis
SPSS 14.0 (Chicago, USA) was employed for data analysis. Ordinal data analysis, one-way analysis of variance and chi-square test were used when appropriate. P = 0.05 was quoted consistently as the statistical significance level. Key study indicators included patient health expenditure, hospitalization, use of second-line anti-TB drugs, diagnostic and treatment delays. Median was used instead of the means to describe variables such as expenditure and delays whose distributions were highly skewed. According to the international standards of TB care, all uncomplicated patients should receive the treatment regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol [23]. We hypothesized that better TB and hospitals collaboration would result in better compliance of the national TB guideline, i.e., less use of second-line anti-TB drugs, less hospitalization, and less use of sophisticated examinations (not required in these cases), which leads to lower patient health expenditure and shorter delays. In another word, the better model would better comply with national TB guidelines and present better study indicators such as lower patient expenditure and shorter delays.

Diagnostic delay is the period from a patient’s first contact of healthcare until his/her TB diagnosis. According to the national guideline, TB should be diagnosed in dispensaries. In practice, TB is often diagnosed in hospitals. Here, the place of actual TB diagnosis is defined as where the patient was first informed of their TB diagnosis through results of sputum microscopy examination. Treatment delay is the period between TB diagnosis and the start of the TB chemotherapy. In this study, the TB treatment period was recorded in patient charts. The actual TB treatment period was usually longer than the recommended six months. Patients could not enjoy free treatment for the extra time exceeding the standard TB treatment time.

A household is defined as incurring catastrophic spending due to TB treatment if the patient reported health expenditure exceeding 40% of his/her household annual non-subsistence spending, which equals to total household spending minus food expenditure [24,25]. This indicator was used to measure TB financial burden relative to income in different models.

Results
Table 1 shows that all selected areas achieved over 85% cure rates in 2007. TB notification rates were 60–138 per 100,000 in the poor areas and 27–45 per 100,000 in rich areas. Within each model, rich areas had higher per capita government expenditure on TB control than poor areas.

In total, 293 patients were surveyed. Table 2 shows the number of outpatient and inpatient charts collected in each site and the proportion of those available. In total, 250 outpatient charts and 88 inpatient charts were collected. Patients of the six sites shared similar demographic characters. Their mean age ranged from 42 to 53 years old, and 60% were male. Smear positive cases accounted for around half of patients and no significant differences were identified among models or sites (P = 0.16). The illiteracy rate was the highest in GP site of the dispensary model and SDC site of the specialist model (P < 0.05). The majority of patients in the dispensary and specialist sites were farmers. Over 75% of patients were entitled to a health insurance program, i.e., basic employee and resident health insurance in urban areas or new cooperative medical insurance scheme in rural areas.

Patient care pathway and TB diagnosis
On average, a patient visited 3 health providers throughout the whole course of TB diagnosis and treatment, ranging from 4 in the specialist sites to 2.2 in the integrated sites (P < 0.001). Hospitals were the major place for TB diagnosis. 37% of patients in the dispensary sites were diagnosed in general hospitals, while 56% in the specialist sites were diagnosed in specialist hospitals. Mixed results were found in the dispensary sites, with 59% patients in the ZD site diagnosed in the general hospitals versus only 14% in the GP site. Over 73% of patients received computerised tomography scan in the specialist sites and the ZD site of the dispensary model (Table 3).

Although all patients were under the national TB program, a high proportion was treated with second-line anti-TB drugs. We found that 42% in the dispensary sites, 74% in the specialist sites and 19% in integrated sites had used second-line anti-TB drugs. In the specialist sites, 29 patients in the SL site and 9 patients in the SDC site received second-line drugs throughout their TB treatment. Commonly used second-line anti-TB drugs were quinolones (most commonly levofloxacin, but also ciprofloxacin and gatifloxacin), protonamide and p-aminosilic acid.

Patient health expenditures and hospitalization
Patients of the integrated sites reported lower median health expenditure (RMB 2,080/USD 306) than those in the specialist sites (RMB 10,190/USD 1,499, P < 0.001). In the dispensary model, the ZD site had significant higher health expenditure (RMB 6,200/USD 912) compared with the GP site (RMB 935/USD 138, P < 0.001). In the specialist model sites and the ZD site of the dispensary model, high patient health expenditures were observed during the period between TB diagnosis and treatment. During the TB treatment period, patient expenditure was found the highest in the SDC site of the specialist model, followed by the ZD site in the dispensary model and the GN site in the integrated model, and then other sites (Table 4).

One third of patients borrowed money for TB care, while 56% of all patients incurred catastrophic spending due to TB treatment. Patient health expenditure for TB care accounted for 44% of their
Table 1. The general social economic situation and health financing for TB in the three models (2007).  

| The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------|----------------------|----------------------|
| ZD                   | GP                   | SL                   | SDC                   | SC                   | GN                   | Sub-total |
| Population           | 1010,000             | 160,000              | 1080,000              | 1200,000             | 750,000              | 6950,000 |
| Per capita GDP (RMB) | 26,120               | 17,545               | 47,586                | 13,369               | 88,785               | 15,774    |
| TB expenditure per person (RMB) | 0.52 | 1.54 | 0.42 | 0.18 | 0.99 | 0.42 |
| Notification rate of TB patients (per million) | 447 | 1,387 | 269 | 602 | 322 | 999 |
| Reported cure rate of new smear positive TB cases (%) | 93.4 | 90.6 | 89.1 | 99.3 | 88.5 | 89.8 |

1 USD = 6.8 RMB. ZD, GP, SL, SDC, SC and GN are names of the selected sites in each collaboration model.

doi:10.1371/journal.pone.0090596.t001

annual household income, ranging from 73% in the specialist sites to 15% in the integrated sites. Patients who borrowed money to treat TB were more likely to incur catastrophic expenditure (P < 0.001). But no correlation was found between patients who borrowed money or who incurred catastrophic expenditure and who did not have health insurance (P = 0.881 and P = 0.820, respectively).

Patient inpatient expenditure accounted for the majority (68%) of their total health expenditure. In total, 44% were hospitalized. The specialist sites reported the highest hospitalization rates (83.3%, P < 0.001), the highest median inpatient expenditure (RMB 8,900/USD 1,309, P < 0.001) and inpatient days (35 days, P = 0.001), while the integrated sites reported the lowest (Table 5). Big differences were found within the two dispensary sites: the ZD site had higher hospitalization rates than the GP site (65% vs. 12%, P < 0.001), while the integrated sites reported the lowest (Table 5).

Delays

The sites in the integrated model reported the shortest diagnostic delay and total delay compared with the other two models (Table 6). Treatment delay was shorter in the integrated sites compared with the ZD site in the dispensary model (P < 0.01).

Discussion

All patients recruited in this study were uncomplicated cases, i.e., new pulmonary TB cases without drug resistance or severe co-morbidities. According to international and domestic guidelines, they should be treated on an outpatient basis, and be given first-line anti-TB drugs. TB cases should be diagnosed by sputum smear and X-ray, not by sophisticated examinations such as computerized tomography scan [23,26]. Any hospitalization, use of second-line anti TB drugs and sophisticated examinations incurred by these uncomplicated TB cases were highly likely unnecessary. The study focused on uncomplicated cases because they accounted for the majority of TB patients in each model. Results and policy

Table 2. Participants in each site and the general information of the patient survey.

| The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------|----------------------|----------------------|
| ZD                   | GP                   | Sub-total            |
| Age                  | 56 49 53 41 50 46 41 42 42 |
| Male,N(%)            | 33(65) 29(59) 62(62) 28(64) 34(74) 62(69) 32(64) 32(62) 65(63) |
| Married,N(%)         | 42(82) 37(76) 79(79) 29(66) 29(63) 58(64) 31(62) 41(77) 72(70) |
| Illiteracy,N (%)     | 9(18) 15(31) 24(24) 3(7) 14(30) 17(19) 1(2) 3(6) 4(4) |
| Farmer,N (%)         | 30(59) 37(76) 67(67) 15(34) 36(78) 51(57) 1(2) 23(43) 24(23) |
| With medical insurance,N (%) | 45(88) 49(100) 94(94) 36(82) 46(100) 82(91) 35(70) 42(79) 77(75) |
| Per capita annual income (M, RMB) | 5,000 1,533 3,000 3,000 1,708 2,167 12,250 3,500 6,400 |
| Borrowed money due to TB care, N (%) | 11(22) 22(45) 33(33) 20(46) 31(67) 51(57) 11(22) 18(34) 29(28) |
| Smear positive (%)   | 31(61) 29(59) 60(60) 19(43) 29(63) 48(53) 33(69) 20(42) 53(51) |

1 USD = 6.8 RMB, M = Median.

1 GP was significantly higher than SL (χ² = 8.409, P = 0.004), SC (χ² = 14.952, P < 0.001) and GN (χ² = 10.908, P = 0.001), SDC was significantly higher than SL (χ² = 8.187, P = 0.004), SC (χ² = 14.693, P < 0.001) and GN (χ² = 10.627, P = 0.001).

2 GP was significantly higher than SL (χ² = 16.134, P < 0.001) and GN (χ² = 7.825, P = 0.005). SDC was significantly higher than SL (χ² = 17.868, P < 0.001) and GN (χ² = 9.225, P = 0.002). ZD (χ² = 37.013, P < 0.001), SL (χ² = 16.370, P < 0.001) and GN (χ² = 26.889, P < 0.001) were significantly higher than SC.

3 Significantly difference was found among six sites (F = 11.907, P < 0.001). SC was significantly higher than ZD (P = 0.015), GP (P < 0.001), SL (P = 0.001), SDC (P < 0.001) and GN (P < 0.001). ZD was significantly higher than GP (P = 0.005) and SDC (P = 0.0026). SL (P = 0.042) and GN (P = 0.007) were significantly higher than GP.

4 SDC was significantly higher than ZD (χ² = 20.685, P < 0.001), SC (χ² = 20.059, P < 0.001) and GN (χ² = 11.009, P < 0.001).

doi:10.1371/journal.pone.0090596.t002

doi:10.1371/journal.pone.0090596.t001
Table 3. Health care seeking behavior of TB patients in the three models.

| Diagnosis place                  | The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------------------|----------------------|----------------------|----------------------|
|                                  | ZD                   | GP                   | Sub-total            |
| Community health centre/Township hospital,N(%) | 1(2.0) | 0                   | 1(1.0)               |
| General hospital,N(%)            | 30(58.8)            | 7(14.3)              | 37(37.0)             |
| County TB dispensary/Integrated hospital,N(%) | 20(39.2) | 42(85.7)            | 62(62.0)             |
| TB special hospital,N(%)         | NA                  | NA                  | NA                   |

M = Median.

1 SL was significantly higher than ZD (χ² = 6.844, P = 0.009), GP (χ² = 74.037, P < 0.001), SDC (χ² = 11.819, P = 0.001), SC (χ² = 19.388, P < 0.001) and GN (χ² = 55.892, P < 0.001). ZD was significantly higher than GP (χ² = 49.242, P < 0.001) and GN (χ² = 32.534, P < 0.001). SDC was significantly higher than GP (χ² = 37.521, P < 0.001) and GN (χ² = 22.093, P < 0.001). SC was significantly higher than GP (χ² = 28.015, P < 0.001) and GN (χ² = 14.064, P < 0.001).

2 ZD was significantly higher than GP (χ² = 25.997, P < 0.001), SC (χ² = 24.458, P < 0.001) and GN (χ² = 22.319, P < 0.001). SL was significantly higher than GP (χ² = 42.627, P < 0.001), SC (χ² = 40.911, P < 0.001) and GN (χ² = 38.580, P < 0.001). SDC was significantly higher than GP (χ² = 23.631, P < 0.001), SC (χ² = 22.144, P < 0.001) and GN (χ² = 20.065, P < 0.001).

3 Significant difference was found among six sites (F = 22.386, P < 0.001). SL was significantly higher than ZD (p = 0.002) and GP (P < 0.001). SDC was significantly higher than ZD (P < 0.001) and GP (P < 0.001). ZD was significantly higher than SC (P < 0.001) and GN (P < 0.001).

Table 4. Patient health expenditure for TB care in three models.

| Diagnosis place                  | The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------------------|----------------------|----------------------|----------------------|
|                                  | ZD                   | GP                   | Sub-total            |
|                                    |                      |                      |                      |
| Patient survey                    | 51                   | 49                   | 100                  |
| Total health expenditure (M, RMB) | 6,200                | 935                  | 2,380                |
| Health expenditure before diagnosis (M, RMB) | 185                  | 80                   | 100                  |
| Health expenditure between TB diagnosis and DOTS treatment(M, RMB) | 2,000                | 0                    | 0                    |
| DOTS treatment expenditure (M, RMB) | 2,000                | 600                  | 1,160                |
| TB catastrophic expenditure ratio, N (%) | 31(60.8)             | 21(42.9)             | 52(52.0)             |

M = Median.

1 USD = 6.8 RMB, M = Median.

2 29 patients of SL and 9 patients of SDC who were never treated in the TB dispensary, so they were excluded from the calculation of DOTS treatment expenditure. They were treated in the specialist hospital with a median treatment period of 209 days and the median health expenditure of RMB 11,965.

3 Significant difference was found among six sites (F = 18.408, P < 0.001). SL was significantly higher than GP (P < 0.001), SC (P < 0.001) and GN (P < 0.001). ZD was significantly higher than GP (P < 0.001), SC (P < 0.001) and GN (P < 0.001). SDC was significantly higher than GP (P < 0.001), SC (P < 0.001) and GN (P < 0.001).

4 Significant difference was found among seven sites (F = 7.3728, P = 0.011). ZD (P < 0.001) and SDC (P < 0.001) were significantly higher than GP. SDC was significantly higher than GP (P < 0.001) and SC (P = 0.028).

5 ZD was significantly higher than SC (χ² = 9.647, P = 0.002). GP was significantly higher than ZD (χ² = 9.450, P = 0.002). GP (χ² = 21.223, P < 0.001), SC (χ² = 32.918, P < 0.001) and GN (χ² = 23.335, P < 0.001). SDC was significantly higher than GP (χ² = 12.391, P < 0.001), SC (χ² = 22.408, P < 0.001) and GN (χ² = 12.432, P < 0.001).

However, they may tend to treat uncomplicated TB patients because specialist hospitals need to make a profit from treating patients. Another reason may be that patients choose to visit the specialist hospital for their high reputation in TB treatment. In practice, there were almost no TB patients referred from the specialist hospital to the TB dispensary [27]. One reason may be the weakness of government coordination because specialist hospitals are often at a higher governmental level than TB dispensaries. Another reason is that doctors in big hospitals often look down their peers in small clinics such as the TB dispensaries.
Surveys in India and Indonesia found similar problems in TB patient care pathways. Second, we observed a swift transfer of TB patients, which likely to be important to enhance the designated hospital's willingness to run TB clinics.

### General challenges in all sites

Noncompliance to national guidelines was observed in all the three models. Overall, nearly half patients received hospitalization, and a significant proportion of patients were given second-line anti-TB drugs. In the dispensary and specialist model sites, over half patients were hospitalized after TB diagnosis. Early use of second-line anti-TB drug may lead to the amplification of MDR TB. The national survey of drug-resistant TB in 2007 found that MDR TB was linked with inappropriate treatment in specialists.

### Table 5. Hospitalization of TB patients in the three models.

|                      | The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------|----------------------|----------------------|----------------------|
|                      | ZD       | GP     | Sub-total | SL       | SDC     | Sub-total | SC       | GN       | Sub-total |
| Patient survey       | 51      | 49     |          | 44      | 46      |          | 90       | 50       | 53        |
| Total hospitalization | 33(64.7)| 6(12.2)|          | 40(90.9)| 35(76.1)|          | 75(83.3)| 8(16.0) | 7(13.2)   |
| Inpatient days (M)   | 19      | 12     |          | 35      | 30      |          | 35       | 15       | 20        |
| Inpatient expenditure | 5,030   | 3,815  |          | 9,028   | 8,554   |          | 8,900    | 4,010    | 6,000     |
| Hospitalization between TB diagnosis and DOTS treatment | 30(58.8) | 3(6.1) |          | 37(84.1)| 23(50.0)| 60(66.7)| 3(6.0)  | 2(3.8)   |
| Inpatient days (M)   | 19      | 17     |          | 35      | 30      |          | 33       | 15       | 18        |
| Inpatient expenditure | 4,905   | 8,597  |          | 9,150   | 6,450   |          | 7,960    | 2,050    | 4,277     |

1 USD = 6.8 RMB, M = Median.
1 ZD was significantly higher than GP (χ² = 29.910, P < 0.001), SC (χ² = 24.836, P < 0.001) and GN (χ² = 29.122, P < 0.001); SL was significantly higher than ZD (χ² = 9.114, P = 0.003), GP (χ² = 57.389, P < 0.001), SC (χ² = 52.556, P < 0.001) and GN (χ² = 58.115, P < 0.001). SDC was significantly higher than GP (χ² = 39.420, P < 0.001), SC (χ² = 34.980, P < 0.001) and GN (χ² = 39.862, P < 0.001). Significant difference was found among six sites (F = 4.034, P = 0.004). SL was significantly longer than GN (P = 0.028).
2 ZD was significantly higher than GP (χ² = 31.392, P < 0.001), SC (χ² = 32.025, P < 0.001) and GN (χ² = 36.975, P < 0.001). SL was significantly higher than ZD (χ² = 7.255, P = 0.007), GP (χ² = 57.495, P < 0.001), SDC (χ² = 11.761, P = 0.001), SC (χ² = 58.385, P < 0.001) and GN (χ² = 64.510, P < 0.001). SDC was significantly higher than GP (χ² = 22.979, P < 0.001), SC (χ² = 23.487, P < 0.001) and GN (χ² = 27.879, P < 0.001).

### Table 6. Delays of TB patients in three models.

|                      | The Dispensary Model | The Specialist Model | The Integrated Model |
|----------------------|----------------------|----------------------|----------------------|
|                      | ZD       | GP     | Sub-total | SL       | SDC     | Sub-total | SC       | GN       | Sub-total |
| Patient survey       | 51      | 49     |          | 44      | 46      |          | 90       | 50       | 53        |
| Patient delay (M)    | 18(3)   | 41(7)  | 29(7)    | 11(5)   | 15(2)   | 13(3)    | 23(3)    | 24(7)    | 23(7)     |
| Diagnostic delay (M) | 26(2)   | 43(5)  | 35(4)    | 7(4)    | 39(12)  | 23(6)    | 7(1)     | 14(1)    | 11(1)     |
| Treatment delay (M)  | 13(9)   | 12(1)  | 12(1)    | 37(30)* | 18(0)*  | 23(0)*   | 2(1)     | 2(1)     | 2(1)      |
| Total delay (M)      | 57(32)  | 96(33) | 76(32)   | 57(44)* | 70(33)* | 66(36)*  | 32(14)   | 40(25)   | 36(17)    |

*29 patients of SL and 9 patients of SDC who were never treated in the TB dispensary, so they were excluded from the calculation of treatment delay and total delay.
\[ \bar{X} = \text{Mean}, M = \text{Median} \]
hospitals, especially specialist hospitals [34]. Moreover, treatment in hospitals resulted in high financial burdens for TB patients. Despite the free TB treatment policy and the majority of patients being covered by medical insurance, the study found that patients had excessive financial burden. In most insurance schemes, coverage for outpatient care is generally a low percentage while the coverage for hospitalization was around 60–70% of the cost [35]. Importantly, the free TB treatment policy does not cover costs on auxiliary examinations, drugs and hospitalization. A large proportion of patients borrowed money for TB care, and incurred catastrophic expenditure due to TB care. TB expenditure in this study was higher compared with reports in other studies [36], because we selected patients treated in hospitals for comparison purposes.

China’s TB control is at crossroads after 20 years since the Stop TB program implementation. The enactment of the Law of Licensing Medical Practitioners called for gradually phasing out providing clinical care in CDC-based TB dispensaries as the CDC is an institute responsible for preventative care not clinical care. In addition, patients generally do not seek care in the TB dispensary as it has relatively low clinical capacity. Furthermore, TB prevalence rates in China has fallen substantially since the 1990s [7,37]; thus, maintaining TB dispensary may not be cost-effective. The debate now focused on where clinical TB services should be best located.

Although the result of the study cannot be generalised across China, the implication, according to our hypothesis, is that the integrated model may demonstrate better hospital and TB program collaboration, and would be a better direction for reform. We also found that government financial support and regulation in the integrated model way are crucial. This model has an advantage because general hospitals are widely accessible in China. The most important challenge is how to protect patients from being exploited by China’s profit-oriented public hospitals [38,39]. Our study found that TB patients only accounted for a small proportion of total patients, so that the designated hospitals in the integrated models were less interested to profit from these patients. On the other side, the recent reforms on public hospitals have improved government investment for hospitals and limited the margins from drugs in hospital revenues [40]. This study is supportive of the integrated hospital model of TB collaboration as part of the on-going health reforms in China.

Limitations

First, the integrated model and specialist model only operated in limited areas, so that we were not able to select sites with comparable economic development. Second, the study used a facility level analysis, thus it did not draw a representative sample of the three TB models in China. The two facilities in the specialist model and the integrated model showed similar indicator despite their differences in economic development. However, large differences were found between the two facilities in the dispensary model. This reflects great variations in the dispensary model similar to that found in the literature. Third, we only studied uncomplicated TB cases in each model. This study did not address the complicated cases treatment as these cases account for a small proportion of total TB cases and national treatment guidelines are less specific for these cases. Complicated TB cases are commonly treated in specialist hospitals, and this study did not intend to address this role of the specialist hospitals. Fourth, patient per capita income varies greatly across China. We here presented patient health expenditures in both absolute monetary terms, and relatively in relation to catastrophic spending. Patient information on income, expenditure and time may suffer from validity problems due to recall and reporting bias. The problem was minimized as the survey was taken within half a year after treatment completion. Information regarding TB treatment in hospitals and TB dispensaries, where possible, was collected from patient charts to cross-check potential recall problems. Fifth, we did not collect total costs because costs covered by health insurance were not available. Rural health insurance plans have a lower coverage rates than urban health insurance plans. However, 18–30% of participants in urban areas did not have health insurance coverage, which may offset the effects caused by different reimbursement rates between urban and rural areas. Lastly, we did not collect information regarding the proportion of budgets, financing and drug procurement of selected health institutions due to the sensitivity of this information.

Conclusion

All three models of TB care carried high financial burdens for their patients. The integrated model reported the best outcomes. The specialist model sites reported the worst outcomes, having the highest rate of unnecessary hospitalization and consequent financial burden on patients. The sites in the dispensary model showed mixed results. The study is supportive of a policy shift towards integrating TB services into general hospitals.

Acknowledgments

We want to express our thanks to colleagues in the Center for Disease Control from Shandong, Shanghai, Guangxi and Zhejiang for facilitation in data collection.

Author Contributions

Conceived and designed the experiments: XW GZ JW QS. Performed the experiments: XW GZ JW JY QS. Analyzed the data: XW GZ JY QS. Contributed reagents/materials/analysis tools: XW QS. Wrote the paper: JW GZ JY QS. Contributed reagents/materials/analysis tools: XW QS. The manuscript was written: JW GZ JY QS. JW KL MU WW.

References

1. WHO (2012) Global Tuberculosis Report 2012. Geneva: the World Health Organization.
2. WHO (2007) Engaging all health care providers in TB control: guidance on implementing public-private mix approaches. Geneva: Stop TB WHO.
3. Chiang C, Trebuq A, Bilo N (2007) A survey of TB services in hospitals in seven large cities in Asia and North Africa. International Journal of Tuberculosis and Lung Disease 11: 739–746.
4. Ayuo PO, Diero LO, Owino-Ong’or W D, Mungai AW (2008) Causes of delay in diagnosis of pulmonary tuberculosis in patients attending a referral hospital in Western Kenya. East African Medical Journal 85: 263–268.
5. Kiwuwa MS, Charles K, Harriet MK (2005) Patient and health service delay in pulmonary tuberculosis patients attending a referral hospital: a cross-sectional study. BMC Public Health 5: 122.
6. Wang L, Liu X, Huang F, Hennig C, Uplekar M, et al. (2010) Engaging hospitals to meet tuberculosis control targets in China: using the Internet as a tool to put policy into practice. Bull World Health Organ 88: 937–942.
7. China Tuberculosis Control Collaboration (2004) The effect of tuberculosis control in China. The Lancet 364: 417–422.
8. Shan SX, Tao WW, Hao JZ, Yang YJ, Li RZ, et al. (2007) [Study on tuberculosis case registration and referral in special tuberculosis hospital]. The Journal of the Chinese Anti-tuberculosis Association 20: 61–63.
9. WHO (2005) Global Tuberculosis Control: Surveillance, Planning and Financing. Geneva: WHO. pp. 75–78.
10. Hu S, Tang S, Liu Y, Zhao Y, Escobar ML, et al. (2008) Reform of how health care is paid for in China: challenges and opportunities. The Lancet 372: 1846–1853.
25. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, et al. (2007) Protecting households from catastrophic health spending. Health Affairs 26: 972–983.

26. China National Centre for TB Control and Prevention (2008) /China Tuberculosis Prevention and Control Plan: guideline for programme planning and implementation] (2nd edition). Beijing: China Ministry of Health.

27. Zou G, Wei X, Walley JD, Yin J, Sun Q (2012) Factors influencing integration of TB services in general hospitals in two regions of China: a qualitative study. BMC health services research 12: 21.

28. Singh AA, Frieden TR, Khatri GR, Garg R (2004) A survey of tuberculosis hospitals in India. The International Journal of Tuberculosis and Lung Disease 8: 1255–1259.

29. Fan YL (2008) [Analysis of pulmonary tuberculosis cases reported and referred from general hospital from 2005 to 2007]. Chinese Journal of Antituberculosis Association 30: 532–534.

30. Lin SF, Chen QY, Du YC, Lin YM, Dai ZS (2009) [Discussions on strengthening the cooperation between the general hospitals and TB dispensaries to improve the case-detection of pulmonary tuberculosis in Fujian province]. Chinese Journal of Anit-suberculosis Association 31: 26–28.

31. Wang LX, Cheng SM, Xu M, Xu W, Li R, et al. (2007) [Report of the pilot project on public-public mix DOTS in China: cooperation of general hospitals and TB dispensaries on reporting, referring and tracing TB patients]. Chinese Journal of Antituberculosis Association 29: 479–483.

32. Xia S, Wang X, Chen S (2006) [Analysis of the financial burden of pulmonary tuberculosis patients under different management modes in Zhejiang province]. Chinese Journal of Antituberculosis Association 28: 354–358.

33. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375: 1830–1843.

34. Zhao Y, Xu S, Wang I, Chin DP, Wang S, et al. (2012) National survey of drug-resistant tuberculosis in China. The New England journal of medicine 366: 2161–2170.

35. Barber SI, Yao L (2011) Development and status of health insurance systems in China. Int J Health Plann Manage 26: 339–356.

36. Long Q, Smith H, Zhang T, Tang S, Garner P (2011) Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health 11: 2161–2170.

37. WHO (2011) National TB prevalence surveys: global progress, results and lessons learnt. 42nd Union World Conference on Lung Health. Lille, France: The International Union Against Tuberculosis and Lung Disease.

38. Ma J, Li M, Quan H (2008) From a national, centrally planned health system to a system based on the market: lessons from China. Health Affairs 27: 339–356.

39. Yip W, Hsiao WC (2008) The Chinese Health System at a Crossroads. Health Affairs 27: 460–468.

40. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, et al. (2012) Early appraisal of China’s huge and complex health-care reforms. Lancet 379: 833–842.